- Conditions
- Salt-sensitive Hypertension
- Interventions
- Fenoldopam
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 605
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Renal Impairment
- Interventions
- PF-04965842
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Quality of Life, Depression, End Stage Renal Disease, Disability Physical
- Interventions
- CAPABLE Transplant- Open Label Pilot, CAPABLE Transplant- Randomized Control Trial
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure
- Interventions
- QRX-3
- Drug
- Lead sponsor
- Ebima Clifford Okundaye
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Pasedena, Texas
- Conditions
- Hypertension
- Interventions
- CIN-107
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Tampa, Florida
- Conditions
- Cardiomyopathy, Renal Impairment
- Interventions
- Tadalafil, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Postmenopausal, Female
- Interventions
- There will be no intervention.
- Other
- Lead sponsor
- Florida State University
- Other
- Eligibility
- 55 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Tallahassee, Florida
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Renal Impairment
- Interventions
- semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Knoxville, Tennessee
- Conditions
- HIV Infections
- Interventions
- Oral BMS-663068 (pro-drug)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Chronic Hepatitis B Infection
- Interventions
- Pevifoscorvir Sodium (ALG-000184)
- Drug
- Lead sponsor
- Aligos Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Tampa, Florida
- Conditions
- Renal Impairment
- Interventions
- Saroglitazar magnesium
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- DeLand, Florida • San Antonio, Texas
- Conditions
- Healthy, Renal Insufficiency
- Interventions
- Selpercatinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 6
- States / cities
- Anaheim, California • Pleasanton, California • Tustin, California + 3 more
- Conditions
- End Stage Renal Disease, Hemodialysis
- Interventions
- Spironolactone, L-arginine, Placebo
- Drug · Dietary Supplement
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Lupus Nephritis
- Interventions
- None (Observational study)
- Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Charlotte, North Carolina • Columbus, Ohio + 1 more
- Conditions
- Moderate Renal Impairment
- Interventions
- 12mg clofutriben
- Drug
- Lead sponsor
- Sparrow Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 83 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Hyperparathyroidism, Secondary, Kidney Failure, Chronic
- Interventions
- doxercalciferol
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- K-877, Fenofibrate, Placebo (for K-877), Placebo (for Fenofibrate)
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 94 more
- Conditions
- Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
- Interventions
- Elecoglipron, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 33
- States / cities
- Sun City, Arizona • Surprise, Arizona • Concord, California + 29 more
- Conditions
- Kidney Disease, Renal Insufficiency Chronic, Kidney Failure, Chronic, Renal Impairment, Renal Insufficiency, End Stage Kidney Disease
- Interventions
- LY3841136
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Miami Lakes, Florida • Orlando, Florida
- Conditions
- Acute Kidney Injury
- Interventions
- MB-102-- single dose of 4 µmol/kg, MB-102-- single dose of 130 mg, MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart, MB-102-- two doses of 130 mg 24 hours apart, Iohexol, QuantumLeap, Radiance, Brilliance (1 or 2 sensors), Brilliance (2-part sensor)
- Drug · Device
- Lead sponsor
- MediBeacon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- Edgewater, Florida • Orlando, Florida • St Louis, Missouri
- Conditions
- Chronic Kidney Disease
- Interventions
- Exercise training, Usual Care
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Advanced Solid Tumors
- Interventions
- panobinostat (LBH589)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Dementia, Cognition, End-stage Renal Disease
- Interventions
- Not listed
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois